New drug combo aims to tackle Hard-to-Treat cancers

NCT ID NCT03919292

Terminated Disease control Sponsor: Virginia Commonwealth University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: neratinib and divalproex sodium (valproate)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors, especially those with RAS mutations, which are hard to treat.
What could go wrong: This is an early phase 1/2 trial with a small number of participants (83). The drug combo may not work or could cause serious side effects. Success is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classical glioblastoma colonic neoplasm colorectal cancer Disease Progression neoplasm ocular melanoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Locations

Virginia Commonwealth University Massey Cancer Center

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.